Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoproliferative Disorders 1Herpes Simplex 1Glioblastoma 1Fatigue Syndrome, Chronic 1Fatigue 1Epstein-Barr Virus Infections 1

Interventions

pembrolizumab 2Rituximab 2valomaciclovir 1threonic acid 1otelixizumab 1brincidofovir 1Valganciclovir 1Valacyclovir 1Tenofovir 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Matrix-M 1Magnesium Sulfate 1Lenalidomide 1Brentuximab Vedotin 1Bevacizumab 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Epstein-Barr Virus Infections × Valganciclovir × Clear all
NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed
30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡